FibroGen Inc [FGEN] stock is trading at $0.34, up 9.76%. An important factor to consider is whether the stock is rising or falling in short-term value. The FGEN shares have gain 15.00% over the last week, with a monthly amount glided 20.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
FibroGen Inc [NASDAQ: FGEN] stock has seen the most recent analyst activity on August 08, 2023, when BofA Securities downgraded its rating to a Underperform and also revised its price target to $2 from $4. Previously, William Blair downgraded its rating to Mkt Perform on June 26, 2023. On June 26, 2023, downgrade downgraded it’s rating to Hold. Raymond James downgraded its rating to a Mkt Perform. BofA Securities downgraded its rating to a Neutral. Stifel upgraded its rating to Buy for this stock on June 02, 2023, and upped its price target to $32. In a note dated January 31, 2023, William Blair upgraded an Outperform rating on this stock.
FibroGen Inc [FGEN] stock has fluctuated between $0.18 and $1.53 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. FibroGen Inc [NASDAQ: FGEN] shares were valued at $0.34 at the most recent close of the market. An investor can expect a potential return of 8135.29% based on the average FGEN price forecast.
Analyzing the FGEN fundamentals
FibroGen Inc [NASDAQ:FGEN] reported sales of 102.85M for the trailing twelve months, which represents a drop of -95.10%. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at 5.7%, Pretax Profit Margin comes in at 5.8%, and Net Profit Margin reading is 1.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is 0.15 and Total Capital is -1.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, FibroGen Inc’s Current Ratio is 2.02. On the other hand, the Quick Ratio is 1.98, and the Cash Ratio is 0.46. Considering the valuation of this stock, the price to sales ratio is 0.34.
Transactions by insiders
Recent insider trading involved Wettig Thane, CEO, that happened on Mar 24 ’25 when 0.14 million shares were purchased. Director, Schoeneck James A completed a deal on Mar 20 ’25 to buy 0.25 million shares. Meanwhile, Director Schoeneck James A bought 50000.0 shares on Mar 21 ’25.
